The Endocrine Society states that the use of puberty-delaying medication or hormone therapy in children is rare and reflects a cautious approach, and that medical treatment is considered appropriate for transgender and gender-diverse teenagers who experience persistent gender dysphoria; the society also cites medical studies indicating that access to such care improves the well-being of transgender and nonbinary people.
2025
high
temporal
Position and summary claim from a major medical specialty society regarding clinical practice and evidence about outcomes.